Table 2.
Clinical feature or frequency of biomarker expression | Total N = 101 | Transgelin Negative N = 68 | Transgelin Positive N = 33 | Frequency positive within category | P=Value |
---|---|---|---|---|---|
| |||||
Age at diagnosis, years; median (range) | 53 (34–94) | 56 (36–94) | 51 (34–90) | 0.22 | |
| |||||
Tumor size, cm (median) | 2.2 (0.6–12.2) | 2.2 {0.6–12.2) | 2.5 (1.0–5.4) | 0.81 | |
| |||||
Surgical Procedure | 0.83 | ||||
Biopsy | 2 (2%) | 1 (2%) | 1 (3%) | 50% | |
Excisional Biopsy | 8 (8%) | 5 (7%) | 3 (9%) | 38% | |
Lumpectomy | 39 (39%) | 25 (37%) | 14 (42%) | 36% | |
Mastectomy | 52 (51%) | 37 (54%) | 15 (46%) | 29% | |
| |||||
Histology | 0.092 | ||||
Ductal | 94 (93%) | 61 (90%) | 33 (100%) | 35% | |
Mixed Lobular | 7 (7%) | 7 (10%) | 0 (0%) | 0% | |
| |||||
Grade (SBR) | 3.1 × 10−5 | ||||
I | 14 (14%) | 12 (18%) | 2 (6%) | 14% | |
II | 34 (34%) | 31 (46%) | 3 (9%) | 9% | |
III | 53 (52%) | 25 (36%) | 28 (85%) | 53% | |
| |||||
Lymph Node Procedure | 0.12 | ||||
Axillary | 57 (56%) | 35 (52%) | 22 (67%) | 39% | |
Sentinel | 23 (23%) | 19 (28%) | 4 (12%) | 17% | |
Both | 11 (11%) | 9 (13%) | 2 (6%) | 18% | |
None | 10 (10%) | 5 (7%) | 5 (15%) | 50% | |
| |||||
Lymph node | 0.65 | ||||
Negative | 45 (50%) | 30 (48%) | 15 (54%) | 33% | |
Positive | 46 (50%) | 33 (52%) | 13 (46%) | 28% | |
| |||||
ER Positivity, ≥1% | 1 × 10−6 | ||||
No | 38 (38%) | 11 (16%) | 27 (82%) | 71% | |
Yes | 63 (62%) | 57 (84%) | 6 (18%) | 10% | |
| |||||
PR Positivity, ≥1% | 1 × 10−6 | ||||
No | 41 (41%) | 14 (21%) | 27 (82%) | 66% | |
Yes | 60 (59%) | 54 (79%) | 6 (18%) | 10% | |
| |||||
Her-2 Positivity, ACIS ≥2.0 | 1.0 | ||||
No | 90 (89%) | 60 (88%) | 30 (91%) | 33% | |
Yes | 11 (11%) | 8 (12%) | 3 (9%) | 27% | |
| |||||
Triple Negative | 1 × 10−6 | ||||
No | 67 (66%) | 60 (88%) | 7 (21%) | 10% | |
Yes | 34 (34%) | 8 (12%) | 26 (79%) | 77% | |
| |||||
High Ki-67 expression, ≥ 10% | 0.0025 | ||||
No | 44 (44%) | 37 (54%) | 7 (21%) | 16% | |
Yes | 57 (56%) | 31 (46%) | 26 (79%) | 46% |